Erratum to: Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: The results from the MAGIC study (Journal of Gastroenterology DOI: 10.1007/s00535-013-0839-5);Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: The results from the MAGIC study

Journal of Gastroenterology

Volumn 49, Issue 5, 2014, Pages 814-824

  Uemura, Naomi ^a   Sugano, Kentaro ^b   Hiraishi, Hideyuki ^c   Shimada, Kazuyuki ^b   Goto, Shinya ^d   Uchiyama, Shinichiro ^e   Okada, Yasushi ^f   Origasa, Hideki ^g   Ikeda, Yasuo ^h  

^a National Center for Global Health and Medicine   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

^d TOKAI UNIVERSITY   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^g UNIVERSITY OF TOYAMA   (Japan)

^h WASEDA UNIVERSITY   (Japan)

Author keywords

Cardiovascular patients; Endoscopy; Gastroduodenal erosion; Gastroduodenal ulcer; Low dose aspirin

Indexed keywords

ACETYLSALICYLIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; ANTITHROMBOCYTIC AGENT;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; COLON CANCER; CONTROLLED STUDY; DIABETES MELLITUS; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM INJURY; DRUG USE; ESOPHAGUS CANCER; FEMALE; GASTRODUODENAL EROSION; GASTRODUODENAL INJURY; HEART PROTECTION; HELICOBACTER INFECTION; HUMAN; JAPAN; JAPANESE (PEOPLE); LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUCOSAL DISEASE; MUCOSAL EROSION; MULTICENTER STUDY; OBSERVATIONAL STUDY; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; STOMACH CANCER; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; GASTROINTESTINAL DISEASES; INTESTINE MUCOSA; MIDDLE AGED; PATHOLOGY; STOMACH MUCOSA;

AGED; ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTRIC MUCOSA; GASTROINTESTINAL DISEASES; HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS; HUMANS; INTESTINAL MUCOSA; JAPAN; MALE; MIDDLE AGED; PEPTIC ULCER; PLATELET AGGREGATION INHIBITORS; PREVALENCE; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 84901462336     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0868-0     Document Type: Erratum

References (29)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ. 2002;324:71-86.
2. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162:2197-202. (Pubitemid 35231588)
3. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003;163:2006-10. (Pubitemid 37151241)
4. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60.
5. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106:388-91. (Pubitemid 34778969)
6. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:161-72. (Pubitemid 34073943)
7. García Rodríguez LA, Hernández-Díaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001;52:563-71.
8. Sakamoto C, Sugano K, Ota S, et al. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol. 2006;62:765-72. (Pubitemid 44289508)
9. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22:795-801. (Pubitemid 41564359)
10. Chiba T, Seno H, Marusawa H, Wakatsuki Y, Okazaki K. Host factors are important in determining clinical outcomes of Helicobacter pylori infection. J Gastroenterol. 2006;41:1-9.
11. Origasa H, Goto S, Shimada K, MAGIC Investigators, et al. Prospective cohort study of gastrointestinal complications and vascular diseases in patients taking aspirin: rationale and design of the MAGIC Study. Cardiovasc Drugs Ther. 2011;25:551-60.
12. Bhatt DL, Scheiman J, Abraham NS, et al. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52:1502-17.
13. Guidelines for EBM Based Clinical Practice of Gastric Ulcer. 2nd ed. Team on EBM Based Clinical Practice of Gastric Ulcer, editors, Jiho; 2007. p. 101-10 (in Japanese).
14. Nema H, Kato M, Katsurada T, et al. Endoscopic survey of low-dose-aspirin-induced gastroduodenal mucosal injuries in patients with ischemic heart disease. J Gastroenterol Hepatol. 2008;23(Suppl 2):S234-6.
15. Shiotani A, Sakakibara T, Yamanaka Y, et al. Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin. J Gastroenterol. 2009;44:126-31.
16. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23:163-73. (Pubitemid 46201599)
17. Shiotani A, Nishi R, Yamanaka Y, et al. Renin-angiotensin system associated with risk of upper GI mucosal injury induced by low dose aspirin: renin angiotensin system genes' polymorphism. Dig Dis Sci. 2011;56:465-71.
18. Shiotani A, Sakakibara T, Yamanaka Y, et al. The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy. J Gastroenterol. 2009;44:717-25.
19. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sáinz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2002;16:779-86. (Pubitemid 34407526)
20. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996;348:1413-6. (Pubitemid 26395236)
21. Nema H, Kato M, Katsurada T, et al. Investigation of gastric and duodenal mucosal defects caused by low-dose aspirin in patients with ischemic heart disease. J Clin Gastroenterol. 2009;43:130-2.
22. Dammann HG, Burkhardt F, Wolf N. Enteric costing of aspirin significantly decreases gastroduodenal mucosal lesions. Aliment Pharmacol Ther. 1999;13:1109-14. (Pubitemid 29374114)
23. Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103:2465-73.
24. Sugano K, Matsumoto Y, Itabashi T, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2011;46:724-35.
25. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and esophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:119-25.
26. Moore A, Bjarnason I, Cryer B, et al. Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm. Clin Gastroenterol Hepatol. 2009;7:1156-63.
27. Graham DY. Endoscopic ulcers are neither meaningful nor validated as a surrogate for clinically significant upper gastrointestinal harm. Clin Gastroenterol Hepatol. 2009;7:1147-50.
28. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31-41.
29. Yang P, Zhou Y, Chen B, et al. Aspirin use and the risk of gastric cancer: a meta-analysis. Dig Dis Sci. 2010;55:1533-9.